Mikkel Wandahl Pedersen
Technik-/Wissenschafts-/F&E-Leiter bei NYKODE THERAPEUTICS
Profil
Mikkel Wandahl Pedersen is currently the Chief Scientific Officer at Nykode Therapeutics ASA since 2021.
Previously, he worked as the Chief Scientific Officer at Symphogen A.
He holds a doctorate degree from the University of Copenhagen.
Aktive Positionen von Mikkel Wandahl Pedersen
| Unternehmen | Position | Beginn |
|---|---|---|
| NYKODE THERAPEUTICS | Technik-/Wissenschafts-/F&E-Leiter | 01.06.2021 |
Ehemalige bekannte Positionen von Mikkel Wandahl Pedersen
| Unternehmen | Position | Ende |
|---|---|---|
Symphogen A/S
 Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Mikkel Wandahl Pedersen
| University of Copenhagen | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| NYKODE THERAPEUTICS | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Health Technology |
